PROGRAM CHAIR
Jared Weiss, MD
Professor of Medicine
Section Chief of Thoracic and Head/Neck Oncology
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
PROGRAM OVERVIEW
This virtually live / enduring activity has been designed to meet the educational needs of community-based and academic medical oncologists and other healthcare professionals, including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies. We aim to help HCPs better consider immunopathologic factors in the pathogenesis of NSCLC and strategies for targeting NSCLC based on appropriate application of clinical biomarkers; recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC and, lastly, to evaluate the latest biomarkers for selection of therapies for the management of NSCLC.
TARGET AUDIENCE
This activity is designed to meet the educational needs of both community based and academic medical oncologists and other health care professionals including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC
- Evaluate the latest biomarkers for selection of therapies for the front-line management of NSCLC
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with NSCLC.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Jared Weiss, MD | Discloses that he or an immediate family member has stock or other ownership interest in, Achilles Therapeutics, Nektar, Vesselon, Nuvalent, Lyell Immunopharma, En Fuego Therapeutics, Vertex. He has worked in a consulting / advisory role for AstraZeneca, EMD Serono (DSMB), Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Eli Lilly, Blueprint Medicines, Pfizer, Saatchi Wellness, Jazz Pharmaceuticals, Boehringer Ingelheim, Regeneron, Genmab, SDP Oncology and BeiGene. He has also received research funding provided to University of North Carolina from Mirati Therapeutics, Sumitomo Dainippon Pharma Oncology, Boehringer Ingelheim, PDS Biotechnology, Merck, AstraZeneca / MedImmune, Amgen, CareFusion, G1 Therapeutics, Immunicum, Loxo@Lilly. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for enduring this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
PROGRAM OVERVIEW
This virtually live / enduring activity has been designed to meet the educational needs of community-based and academic medical oncologists and other healthcare professionals, including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies. We aim to help HCPs better consider immunopathologic factors in the pathogenesis of NSCLC and strategies for targeting NSCLC based on appropriate application of clinical biomarkers; recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC and, lastly, to evaluate the latest biomarkers for selection of therapies for the management of NSCLC.TARGET AUDIENCE
This activity is designed to meet the educational needs of both community based and academic medical oncologists and other health care professionals including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies.LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:- Recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC
- Evaluate the latest biomarkers for selection of therapies for the front-line management of NSCLC
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with NSCLC. CNE Credits: 1.0 ANCC Contact Hour.CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
| Jared Weiss, MD | Discloses that he or an immediate family member has stock or other ownership interest in, Achilles Therapeutics, Nektar, Vesselon, Nuvalent, Lyell Immunopharma, En Fuego Therapeutics, Vertex. He has worked in a consulting / advisory role for AstraZeneca, EMD Serono (DSMB), Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Eli Lilly, Blueprint Medicines, Pfizer, Saatchi Wellness, Jazz Pharmaceuticals, Boehringer Ingelheim, Regeneron, Genmab, SDP Oncology and BeiGene. He has also received research funding provided to University of North Carolina from Mirati Therapeutics, Sumitomo Dainippon Pharma Oncology, Boehringer Ingelheim, PDS Biotechnology, Merck, AstraZeneca / MedImmune, Amgen, CareFusion, G1 Therapeutics, Immunicum, Loxo@Lilly. |
CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer. Douglas Cox, MSN, MHA, RN Ultimate Medical Academy/CCM – Lead Nurse Planner The reviewer of this activity has nothing to disclose.Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for enduring this activity. To receive CME/CNE credit participants must:- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use. For CME questions, please contact Med Learning Group at [email protected]. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]PROGRAM OVERVIEW
This virtually live / enduring activity has been designed to meet the educational needs of community-based and academic medical oncologists and other healthcare professionals, including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies. We aim to help HCPs better consider immunopathologic factors in the pathogenesis of NSCLC and strategies for targeting NSCLC based on appropriate application of clinical biomarkers; recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC and, lastly, to evaluate the latest biomarkers for selection of therapies for the management of NSCLC.TARGET AUDIENCE
This activity is designed to meet the educational needs of both community based and academic medical oncologists and other health care professionals including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies.LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:- Consider immunopathologic factors in the pathogenesis of non-small-cell lung cancer (NSCLC) and strategies for targeting NSCLC based on the appropriate application of clinical biomarkers
- Recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC
- Evaluate the latest biomarkers for selection of therapies for the front-line management of NSCLC
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with NSCLC. CNE Credits: 1.0 ANCC Contact Hour.CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
| Jared Weiss, MD | Discloses that he or an immediate family member has stock or other ownership interest in, Achilles Therapeutics, Nektar, Vesselon, Nuvalent, Lyell Immunopharma, En Fuego Therapeutics, Vertex. He has worked in a consulting / advisory role for AstraZeneca, EMD Serono (DSMB), Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Eli Lilly, Blueprint Medicines, Pfizer, Saatchi Wellness, Jazz Pharmaceuticals, Boehringer Ingelheim, Regeneron, Genmab, SDP Oncology and BeiGene. He has also received research funding provided to University of North Carolina from Mirati Therapeutics, Sumitomo Dainippon Pharma Oncology, Boehringer Ingelheim, PDS Biotechnology, Merck, AstraZeneca / MedImmune, Amgen, CareFusion, G1 Therapeutics, Immunicum, Loxo@Lilly. |
CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer. Douglas Cox, MSN, MHA, RN Ultimate Medical Academy/CCM – Lead Nurse Planner The reviewer of this activity has nothing to disclose.Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with ineligible companies related to the content of this CME/CE activity:- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sylvia Hanna, MD Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for enduring this activity. To receive CME/CNE credit participants must:- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use. For CME questions, please contact Med Learning Group at [email protected]. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]RELEASED DATE: December 21, 2022
EXPIRATION DATE: December 21, 2023
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
